Ligand validation:1LA2

NAD: NICOTINAMIDE-ADENINE-DINUCLEOTIDE

NAD is a Ligand Of Interest in 1LA2 designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
1LA2_NAD_C_902	38%	9%	0.204	0.906	2.59	1.91	9	11	2	0	100%	1
1LA2_NAD_B_901	21%	9%	0.24	0.848	2.62	1.82	9	9	1	0	100%	1
1LA2_NAD_A_900	17%	9%	0.266	0.847	2.61	1.81	9	10	2	0	100%	1
1LA2_NAD_D_903	16%	9%	0.258	0.826	2.59	1.83	11	9	2	0	100%	1
1P1H_NAD_B_660	80%	15%	0.12	0.97	2.51	1.26	10	6	3	0	100%	1
1P1I_NAD_A_650	55%	20%	0.185	0.954	2.17	1.24	8	9	2	0	100%	1
2O2Y_NAD_B_1450	100%	23%	0.024	0.995	1.79	1.4	5	3	1	0	100%	1
3CMC_NAD_R_408	100%	20%	0.016	0.998	1.63	1.74	4	9	0	0	100%	1
4RQU_NAD_B_403	100%	3%	0.019	0.997	3.51	2.61	13	18	0	0	100%	1
3EC7_NAD_A_400	100%	18%	0.025	0.995	1.8	1.74	5	8	1	0	100%	1
4URF_NAD_A_1249	100%	44%	0.034	0.995	0.96	1.2	2	4	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.